Disease Landscape and Forecast Insights

Core to Parkinson’s disease (PD) treatment is the co-prescription of various formulations of the gold-standard SOC levodopa with a range of adjunctive therapies from other drug classes (e.g.,…

Clarivate Epidemiology’s coverage of neuromyelitis optica spectrum disorder (NMOSD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…

Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive muscle weakness; it is a leading genetic cause of death in infants. SMA is divided into four clinical subtypes…

For neurologists, established molecules like leveteriacetam, lamotrigine, and carbamazepine remain the first choice of treatment for epilepsy; however, the new entrants in the market are evoloving…

Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…

Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Clarivate Epidemiology’s coverage of MS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of MS for each country, as well…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple sclerosis patient populations covering 171 countries and…

Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…